Faktoren der Tumorbiologie bei peripheren Nervenscheidentumoren: eine vergleichende immunhistochemische Studie bei Mensch und Hund
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Abschlussarbeit Buch |
| Sprache: | German |
| Veröffentlicht: |
Gießen
VVB Laufersweiler Verlag
2017
|
| Schriftenreihe: | édition scientifique
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | VI, 214 Seiten Diagramme, Illustrationen 21 cm x 14.6 cm, 218 g |
| ISBN: | 3835965530 9783835965539 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV044490350 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 170915s2017 a||| m||| 00||| ger d | ||
| 015 | |a 17N15 |2 dnb | ||
| 016 | 7 | |a 1129116786 |2 DE-101 | |
| 020 | |a 3835965530 |c : (Broschur : EUR 34.80 (DE), EUR 35.80 (AT)) |9 3-8359-6553-0 | ||
| 020 | |a 9783835965539 |c : (Broschur : EUR 34.80 (DE), EUR 35.80 (AT)) |9 978-3-8359-6553-9 | ||
| 035 | |a (OCoLC)983777924 | ||
| 035 | |a (DE-599)DNB1129116786 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a ger | |
| 049 | |a DE-188 | ||
| 100 | 1 | |a Püschel, Louisa |e Verfasser |0 (DE-588)1130183416 |4 aut | |
| 245 | 1 | 0 | |a Faktoren der Tumorbiologie bei peripheren Nervenscheidentumoren |b eine vergleichende immunhistochemische Studie bei Mensch und Hund |c eingereicht von Louisa Püschel |
| 264 | 1 | |a Gießen |b VVB Laufersweiler Verlag |c 2017 | |
| 300 | |a VI, 214 Seiten |b Diagramme, Illustrationen |c 21 cm x 14.6 cm, 218 g | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 0 | |a édition scientifique | |
| 502 | |b Dissertation |c Justus-Liebig-Universität Gießen |d 2017 | ||
| 650 | 7 | |a thesis |2 cabt | |
| 650 | 7 | |a immunology |2 cabt | |
| 650 | 7 | |a carcinogenesis |2 cabt | |
| 650 | 7 | |a histology |2 cabt | |
| 650 | 7 | |a neoplasms |2 cabt | |
| 650 | 0 | 7 | |a Dissertation |0 (DE-588)4012494-0 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4113937-9 |a Hochschulschrift |2 gnd-content | |
| 689 | 0 | 0 | |a Dissertation |0 (DE-588)4012494-0 |D s |
| 689 | 0 | |5 DE-604 | |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=029890317&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-029890317 | ||
Datensatz im Suchindex
| _version_ | 1804177834724294656 |
|---|---|
| adam_text | INHALTSVERZEICHNIS
ABKUERZUNGSVERZEICHNIS.............................................................................................
1
1 EINLEITUNG UND ZIEL DER
STUDIE..........................................................................
4
2
LITERATURUEBERSICHT.................................................................................................5
2.1 NEUROFIBROMATOSE TYP 1 BEIM MENSCHEN
...............................................................
5
2.1.1 DERMALES/KUTANES
NEUROFIBROM.............................................................................................7
2.1.2 PLEXIFORMES
NEUROFIBROM........................................................................................................
8
2.1.3 DIFFUSES
NEUROFIBROM...............................................................................................................9
2.1.4 PLEXIFORM-DIFFUSES
NEUROFIBROM...........................................................................................
10
2.1.5 MALIGNER PERIPHERER
NERVENSCHEIDENTUMOR........................................................................11
2.2 PERIPHERE NERVENSCHEIDENTUMORE IN DER
VETERINAERMEDIZIN...............................12
2.3 PERIPHERE NERVENSCHEIDENTUMORE BEIM
HUND.....................................................14
2.4 IMMUNOLOGISCHE
EXPRESSIONSPROTEINE..................................................................16
2.4.1 EXPRESSIONSMUSTER PERIPHERER
NERVENSCHEIDENTUMORE....................................................16
2.4.1.1
S100-PROTEIN......................................................................................................................
17
2.4.1.2 EPITHELIALES
MEMBRANANTIGEN...........................................................................................17
2.4.1.3
CLAUDIN-1...........................................................................................................................
18
2.4.1.4
CD90...................................................................................................................................
16
2.4.1.5
MASTZELLTRYPTASE.................................................................................................................
19
2.4.1.6
NEUROFILAMENT....................................................................................................................
19
2.4.2 FAKTOREN DES
TUMORWACHSTUMS.........................................................................................
20
2.4.2.1 DIE ACHT KENNZEICHEN DER TUMORENTSTEHUNG
................................................................
20
2.4.2.2 PROLIFERATIONSMARKER
KI-67................................................................................................23
2.4.2.3 WACHSTUMSFAKTORREZEPTOREN UND NEUREGULIN-1
..............................................................
23
EPIDERMALER
WACHSTUMSFAKTORREZEPTOR-2...................................................................................
25
EPIDERMALER
WACHSTUMSFAKTORREZEPTOR-3...................................................................................25
NEUREGULIN-1..................................................................................................................................
25
2.4.2.4
CD44...................................................................................................................................
27
2.4.2.5
NEUROFIBROMIN-SIGNALWEG.................................................................................................27
MTOR...............................................................................................................................................
28
RHO.................................................................................................................................................
29
MEK1/2...........................................................................................................................................29
2.4.2.6 T
RANSKRIPTIONSFAKTOREN.....................................................................................................
29
P
AX7................................................................................................................................................30
S
OX9................................................................................................................................................30
2.4.3 DIFFERENZIERUNGSMARKER CANINER
PNST.................................................................................30
2.4.3.1
PERIAXIN...............................................................................................................................
31
2.4.3.2 A-SMOOTH MUSCLE
ACTIN....................................................................................................
31
2.4.3.3 SAURES
GLIAFASERPROTEIN....................................................................................................
32
2.4.3.4
NERVENWACHSTUMSFAKTORREZEPTOR.....................................................................................
32
3 MATERIAL UND
METHODEN......................................................................................33
3.1
MATERIAL.......................................................................................................................
33
3.1.1 PATIENTENKOLLEKTIV -
MENSCHEN............................................................................................
33
3.1.2 PATIENTENKOLLEKTIV -
HUNDE..................................................................................................
33
3.1.3
ANTIKOERPER..............................................................................................................................
35
3.1.4 LOESUNGEN UND IMMUNHISTOCHEMISCHE
REAGENZIEN...........................................................36
3.1.5 GEBRAUCHS- UND
VERBRAUCHSMATERIALIEN.............................................................................36
3.1.6
GERAETE.....................................................................................................................................36
3.2
METHODEN....................................................................................................................
36
3.2.1
SCHNITTHERSTELLUNG.................................................................................................................
36
3.2.2 PROTOKOLL
SILAN-BESCHICHTUNG...............................................................................................
36
3.2.3
TISSUE-MICROARRAY-HERSTELLUNG............................................................................................37
3.2.4
HAEMATOXYLIN-EOSIN-FAERBUNG................................................................................................
37
3.2.5
IMMUNHISTOCHEMIE...............................................................................................................
38
3.2.5.1 ANSATZ
ANTIKOERPER..............................................................................................................36
3.2.5.2 PROTOKOLL IMMUNHISTOCHEMIE, EINFACHFAERBUNG
.................................................................
38
3.2.5.3 PROTOKOLL IMMUNHISTOCHEMIE, DOPPELFAERBUNG
..................................................................
39
3.2.6
EVALUATIONSMETHODEN...........................................................................................................40
3.2.6.1
QUALITATIV.............................................................................................................................41
3.2.6.2
SEMIQUANTITATIV..................................................................................................................
43
3.2.6.3
QUANTITATIV..........................................................................................................................44
3.2.6.4 GRADUIERUNGSSCHEMA
SARKOME.......................................................................................
45
3.2.7 STATISTISCHE
AUSWERTUNG......................................................................................................
46
4
ERGEBNISSE................................................................................................................
50
4.1 KLINISCHE DATEN
...........
.............................................................................................
50
4.1.1 HUMANE
NEUROFIBROME.........................................................................................................50
TUMORSUBTYPEN UND ALTER BEI
PROBENENTNAHME.........................................................................50
TUMORSUBTYPEN UND
LOKALISATION.................................................................................................51
4.1.2 CANINE MALIGNE PERIPHERE NERVENSCHEIDENTUMORE
..........................................................
52
4.1.3 VERGLEICH MENSCH - HUND: TUMORTYPEN UND
LOKALISATION................................................53
4.1.4 VERGLEICH MENSCH - HUND: TUMORTYPEN UND ALTER
...........................................................
54
4.2
HISTOMORPHOLOGIE......................................................................................................
54
4.2.1 HUMANE
NEUROFIBROME.........................................................................................................54
4.2.2 CANINE MALIGNE PERIPHERE NERVENSCHEIDENTUMORE
..........................................................
55
4.3
IMMUNHISTOLOGIE.......................................................................................................
58
4.3.1 MENSCH: EXPRESSIONSMUSTER HUMANER P N
ST...................................................................59
4.3.1.1
S100-PROTEIN.......................................................................................................................59
4.3.1.2 EPITHELIALES
MEMBRANANTIGEN...........................................................................................
60
4.3.1.3
CD90....................................................................................................................................62
4.3.1.4
MASTZELLTRYPTASE.................................................................................................................
64
4.3.1.5
NEUROFILAMENT.....................................................................................................................65
4.3.2 MENSCH: DIFFERENZIERUNGSMARKER CANINER MPNST
...........................................................
66
4.3.2.1
PERIAXIN................................................................................................................................68
4.3.2.2 A-SMOOTH MUSCLE
ACTIN....................................................................................................
70
4.3.2.3 SAURES GLIAFASERPROTEIN.......................................
71
4.3.2.4 NERVENWACHSTUMSFAKTORREZEPTOR
.....................................................................................
72
4.3.3 HUND: EXPRESSIONSMUSTER CANINER PNST
..........................................................................
73
4.3.3.1
S100-PROTEIN.......................................................................................................................73
4.3.3.2 EPITHELIALES
MEMBRANANTIGEN...........................................................................................
74
4.3.3.3
CLAUDIN-1............................................................................................................................
74
4.3.3.4
CD90....................................................................................................................................76
4.3.3.5
MASTZELLEN..........................................................................................................................
77
4.3.3.6
NEUROFILAMENT.....................................................................................................................78
4.3.4 HUND: DIFFERENZIERUNGSMARKER CANINER
MPNST................................................................79
4.3.4.1
PERIAXIN................................................................................................................................79
4.3.4.2 A-SMOOTH MUSCLE
ACTIN.....................................................................................................80
4.3.4.3 SAURES
GLIAFASERPROTEIN...................................................................................................
62
4.3.4.4 DOPPELFAERBUNG A-SMA UND
GFAP....................................................................................83
4.3.4.5
NERVENWACHSTUMSFAKTORREZEPTOR......................................................................................84
4.3.5 VERGLEICH MENSCH - HUND:
EXPRESSIONSMUSTER................................................................85
4.3.5.1
S100-PROTEIN.......................................................................................................................85
4.3.5.2
CD90..................................................................................................................................
86
4.3.5.3
MASTZELLTRYPTASE..................................................................................................................87
4.3.5.4
NEUROFILAMENT.....................................................................................................................86
4.3.5.5
PERIAXIN................................................................................................................................69
4.3.5.6 SAURES
GLIAFASERPROTEIN.....................................................................................................90
4.3.5.7
NERVENWACHSTUMSFAKTORREZEPTOR......................................................................................91
4.3.6 MENSCH: FAKTOREN DES
TUMORWACHSTUMS.........................................................................
91
4.3.6.1
KI-67-LNDEX........................................................................................................................91
4.3.6.2
ZELLULARITAET.........................................................................................................................93
4.3.6.3 EPIDERMALER
WACHSTUMSFAKTORREZEPTOR-2........................................................................93
4.3.6.4 EPIDERMALER
WACHSTUMSFAKTORREZEPTOR-3........................................................................95
4.3.6.5
NEUREGULIN-1.......................................................................................................................
97
NEUREGULIN-1 UND ANZAHL VON
AXONEN.........................................................................................99
4.3.6.6 0 0 4 4
.................................................................................................................................
100
4.3.6.7
MTOR..................................................................................................................................103
4.3.6.8
RHO....................................................................................................................................105
4.3.6.9
MEK...................................................................................................................................106
4.3.6.10
PMEK............................................................................................................................108
4.3.6.11
SOX9..............................................................................................................................109
4.3.6.12
PAX7..............................................................................................................................111
4.3.7 HUND: FAKTOREN DES
TUMORWACHSTUMS............................................................................
114
4.3.7.1
KI-67-LNDEX.......................................................................................................................114
4.3.7.2
ZELLULARITAET.......................................................................................................................
115
4.3J.3
NEUREGULIN-1.....................................................................................................................
115
4.3.8 VERGLEICH MENSCH - HUND: FAKTOREN DES TUMORWACHSTUMS
..........................................
116
4.3.8.1
KI-67-LNDEX.......................................................................................................................116
4.3.8.2
ZELLULARITAET.......................................................................................................................
116
4.3.8.3
NEUREGULIN-1.....................................................................................................................
117
4.4 MENSCH: WEITERE
AUSWERTUNG................................................................................118
4.4.1
FNCLCC-GRAD/NG...............................................................................................................
116
4.4.2 KORRELATIONSBERECHNUNGEN VARIABLEN
UNTEREINANDER.......................................................116
DERMALE/KUTANE
NEUROFIBROME...................................................................................................119
PLEXIFORME
NEUROFIBROME............................................................................................................
120
DIFFUSE UND PLEXIFORM-DIFFUSE
NEUROFIBROME.............................................................................
121
MALIGNE PERIPHERE
NERVENSCHEIDENTUMORE..............................................................................
122
4.5 HUND: WEITERE
AUSWERTUNG....................................................................................
123
4.5.1
FNCLCC-GRAD/AG...............................................................................................................
123
4.5.2
GRADINGVERSUCH...................................................................................................................123
STRATEGIE 1: GRADIERUNG NACH KLASSIERTEN
VARIABLEN................................................................
124
STRATEGIE 2: GRADIERUNG NACH
GRENZWERTEN.............................................................................
126
VERGLEICH GRADINGSTRATEGIEN
UNTEREINANDER.............................................................................
127
VERGLEICH GRADINGSTRATEGIEN UND
FNCLCC..............................................................................
126
VERGLEICH GRADIERUNGSSTRATEGIEN UND
TUMORDIFFERENZIERUNG.................................................129
4.6 VERGLEICH MENSCH - HUND: WEITERE
AUSWERTUNG................................................130
4.6.1
FNCLCC-GRAD/NG.................................................................................................................
130
AUFTRETEN VON NEKROSEN IN HMPNST UND
CMPNST.................................................................
131
IV
MITOSEANZAHL IN HMPNST UND CMPNST
131
5
DISKUSSION...............................................................................................................
133
5.1 VERGLEICH HUMANER UND CANINER
MPNST..............................................................134
5.1.1 KLINISCHE
DATEN....................................................................................................................134
ALTER...............................................................................................................................................134
LOKALISATION...................................................................................................................................135
RASSEPRAEDISPOSITION....................................................................................................................136
5.1.2
HISTOMORPHOLOGIE................................................................................................................
136
5.1.2.1 HISTOGENESE HUMANER NEUROFIBROME
...........................................................................
137
5.1.3 TUMORVERHALTEN VON
MPNST.............................................................................................
138
GRADIERUNGSANSAETZE
HUND.........................................................................................................140
5.1.4 EXPRESSIONSMUSTER PERIPHERER
NERVENSCHEIDENTUMORE.................................................141
S100-PROTEIN................................................................................................................................
142
EPITHELIALES
MEMBRANANTIGEN.....................................................................................................143
CLAUDIN-1......................................................................................................................................143
C D 9 0
............................................................................................................................................
144
MASTZELLEN....................................................................................................................................145
NEUROFILAMENT..............................................................................................................................
146
FAZIT..............................................................................................................................................
146
5.2 DIAGNOSE UND DIFFERENTIALDIAGNOSEN VON CMPNST
...........................................
147
SAURES
GLIAFASERPROTEIN..............................................................................................................
148
NERVENWACHSTUMSFAKTORREZEPTOR...............................................................................................
146
CLAUDIN-1......................................................................................................................................146
PERIAXIN.........................................................................................................................................
149
A-SMA...........................................................................................................................................
149
FAZIT..............................................................................................................................................
150
5.2.1 ABSCHLIESSENDE BEWERTUNG: VERGLEICH MENSCH - HUND
...................................................
151
5.3 TUMORWACHSTUM IN HUMANEN
PNST....................................................................151
5.3.1 WACHSTUMSFAKTOREN UND
REZEPTOREN...............................................................................152
EPIDERMALE WACHSTUMSFAKTORREZEPTOREN-2 UND -3, NEUREGULIN-1
.........................................
152
C D 4 4
............................................................................................................................................
154
5.3.2 INTRAZELLULAERE
SIGNALWEGE..................................................................................................
155
MTOR.............................................................................................................................................
155
RHO...............................................................................................................................................
156
MEK1/2.........................................................................................................................................156
FAZIT..............................................................................................................................................
157
5.3.3
TRANSKRIPTIONSFAKTOREN........................................................................................................157
PA X 7
..............................................................................................................................................
157
S
OX9..............................................................................................................................................
159
5.4 HYPOTHETISCHE SIGNALWEGE IN HUMANEN
PNST...................................................160
DERMALE/KUTANE
NEUROFIBROME...................................................................................................160
DIFFUSE UND PLEXIFORM-DIFFUSE
NEUROFIBROME.............................................................................
161
PLEXIFORME
NEUROFIBROME............................................................................................................
163
MALIGNE PERIPHERE
NERVENSCHEIDENTUMORE..............................................................................
164
FAZIT...............................................................................................................................................
165
5.5
AUSBLICK....................................................................................................................
166
6
ZUSAMMENFASSUNG................................................................................................
168
7
SUMMARY....................................................................................................................
170
8
ABBILDUNGSVERZEICHNIS.....................................................................................
172
9
TABELLENVERZEICHNIS...........................................................................................176
10
LITERATURVERZEICHNIS.....................................................................................
177
11
DANKSAGUNG.........................................................................................................195
12
ERKLAERUNG............................................................................................................196
13
ANHANG...................................................................................................................
197
13.1 LOESUNGEN UND IMMUNHISTOCHEMISCHE
REAGENZIEN............................... 197
13.2 GEBRAUCHS- UND
VERBRAUCHSMATERIALIEN..............................................................198
13.3
GERAETE.........................................................................................................................198
13.4 EVALUIERUNGSSCHEMATA DER VERWENDETEN ANTIKOERPER
.......................................
200
13.5 ROHDATEN CANINE PERIPHERE NERVENSCHEIDENTUMORE
........................................
202
13.6 ROHDATEN HUMANEN PERIPHEREN
NERVENSCHEIDENTUMORE.................................204
|
| any_adam_object | 1 |
| author | Püschel, Louisa |
| author_GND | (DE-588)1130183416 |
| author_facet | Püschel, Louisa |
| author_role | aut |
| author_sort | Püschel, Louisa |
| author_variant | l p lp |
| building | Verbundindex |
| bvnumber | BV044490350 |
| ctrlnum | (OCoLC)983777924 (DE-599)DNB1129116786 |
| format | Thesis Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01809nam a2200433 c 4500</leader><controlfield tag="001">BV044490350</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">170915s2017 a||| m||| 00||| ger d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">17N15</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1129116786</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3835965530</subfield><subfield code="c">: (Broschur : EUR 34.80 (DE), EUR 35.80 (AT))</subfield><subfield code="9">3-8359-6553-0</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783835965539</subfield><subfield code="c">: (Broschur : EUR 34.80 (DE), EUR 35.80 (AT))</subfield><subfield code="9">978-3-8359-6553-9</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)983777924</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1129116786</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">ger</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-188</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Püschel, Louisa</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)1130183416</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Faktoren der Tumorbiologie bei peripheren Nervenscheidentumoren</subfield><subfield code="b">eine vergleichende immunhistochemische Studie bei Mensch und Hund</subfield><subfield code="c">eingereicht von Louisa Püschel</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Gießen</subfield><subfield code="b">VVB Laufersweiler Verlag</subfield><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">VI, 214 Seiten</subfield><subfield code="b">Diagramme, Illustrationen</subfield><subfield code="c">21 cm x 14.6 cm, 218 g</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">édition scientifique</subfield></datafield><datafield tag="502" ind1=" " ind2=" "><subfield code="b">Dissertation</subfield><subfield code="c">Justus-Liebig-Universität Gießen</subfield><subfield code="d">2017</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">thesis</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">immunology</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">carcinogenesis</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">histology</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">neoplasms</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Dissertation</subfield><subfield code="0">(DE-588)4012494-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4113937-9</subfield><subfield code="a">Hochschulschrift</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Dissertation</subfield><subfield code="0">(DE-588)4012494-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=029890317&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029890317</subfield></datafield></record></collection> |
| genre | (DE-588)4113937-9 Hochschulschrift gnd-content |
| genre_facet | Hochschulschrift |
| id | DE-604.BV044490350 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T07:54:23Z |
| institution | BVB |
| isbn | 3835965530 9783835965539 |
| language | German |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029890317 |
| oclc_num | 983777924 |
| open_access_boolean | |
| owner | DE-188 |
| owner_facet | DE-188 |
| physical | VI, 214 Seiten Diagramme, Illustrationen 21 cm x 14.6 cm, 218 g |
| publishDate | 2017 |
| publishDateSearch | 2017 |
| publishDateSort | 2017 |
| publisher | VVB Laufersweiler Verlag |
| record_format | marc |
| series2 | édition scientifique |
| spelling | Püschel, Louisa Verfasser (DE-588)1130183416 aut Faktoren der Tumorbiologie bei peripheren Nervenscheidentumoren eine vergleichende immunhistochemische Studie bei Mensch und Hund eingereicht von Louisa Püschel Gießen VVB Laufersweiler Verlag 2017 VI, 214 Seiten Diagramme, Illustrationen 21 cm x 14.6 cm, 218 g txt rdacontent n rdamedia nc rdacarrier édition scientifique Dissertation Justus-Liebig-Universität Gießen 2017 thesis cabt immunology cabt carcinogenesis cabt histology cabt neoplasms cabt Dissertation (DE-588)4012494-0 gnd rswk-swf (DE-588)4113937-9 Hochschulschrift gnd-content Dissertation (DE-588)4012494-0 s DE-604 DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=029890317&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Püschel, Louisa Faktoren der Tumorbiologie bei peripheren Nervenscheidentumoren eine vergleichende immunhistochemische Studie bei Mensch und Hund thesis cabt immunology cabt carcinogenesis cabt histology cabt neoplasms cabt Dissertation (DE-588)4012494-0 gnd |
| subject_GND | (DE-588)4012494-0 (DE-588)4113937-9 |
| title | Faktoren der Tumorbiologie bei peripheren Nervenscheidentumoren eine vergleichende immunhistochemische Studie bei Mensch und Hund |
| title_auth | Faktoren der Tumorbiologie bei peripheren Nervenscheidentumoren eine vergleichende immunhistochemische Studie bei Mensch und Hund |
| title_exact_search | Faktoren der Tumorbiologie bei peripheren Nervenscheidentumoren eine vergleichende immunhistochemische Studie bei Mensch und Hund |
| title_full | Faktoren der Tumorbiologie bei peripheren Nervenscheidentumoren eine vergleichende immunhistochemische Studie bei Mensch und Hund eingereicht von Louisa Püschel |
| title_fullStr | Faktoren der Tumorbiologie bei peripheren Nervenscheidentumoren eine vergleichende immunhistochemische Studie bei Mensch und Hund eingereicht von Louisa Püschel |
| title_full_unstemmed | Faktoren der Tumorbiologie bei peripheren Nervenscheidentumoren eine vergleichende immunhistochemische Studie bei Mensch und Hund eingereicht von Louisa Püschel |
| title_short | Faktoren der Tumorbiologie bei peripheren Nervenscheidentumoren |
| title_sort | faktoren der tumorbiologie bei peripheren nervenscheidentumoren eine vergleichende immunhistochemische studie bei mensch und hund |
| title_sub | eine vergleichende immunhistochemische Studie bei Mensch und Hund |
| topic | thesis cabt immunology cabt carcinogenesis cabt histology cabt neoplasms cabt Dissertation (DE-588)4012494-0 gnd |
| topic_facet | thesis immunology carcinogenesis histology neoplasms Dissertation Hochschulschrift |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=029890317&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT puschellouisa faktorendertumorbiologiebeiperipherennervenscheidentumoreneinevergleichendeimmunhistochemischestudiebeimenschundhund |